The 10th China Pharmaceutical Innovation and Investment Conference, jointly organized by HKEX (00388) and the China Pharmaceutical Innovation and Development Association, was successfully held in Nanjing from October 26 to 27. The event brought together representatives from numerous domestic and international institutions and government departments. Participants engaged in in-depth discussions on pharmaceutical R&D achievements and investment trends while collectively envisioning the future of China's pharmaceutical industry.

At the opening ceremony, Bonnie Chan, CEO of HKEX, emphasized the critical role of capital markets in accelerating the globalization of China's innovative pharmaceutical companies. She highlighted HKEX's commitment to building an efficient and diversified international financing platform to support the growth of biotech enterprises.

This year, Hong Kong's healthcare IPO market has been exceptionally active, ranking first globally in fundraising volume. Zhang Shuming, Head of Listing and Issuance Services for Asia at HKEX, noted during the forum that the exchange continues to play a vital role in facilitating global biopharma companies' listings. He attributed the strong performance of Hong Kong's healthcare financing market to three interconnected factors: continuous regulatory improvements, a steady influx of high-quality innovative firms, and active investor participation.

Market conditions have significantly improved in 2025, with Hong Kong reclaiming its position as the preferred listing destination for biotech companies. So far, Hong Kong has completed 12 biotech IPOs, raising a total of $1.3 billion—the highest globally. Additionally, follow-on financing in the biotech sector remains robust, with $4.1 billion raised year-to-date. This reflects recovering market confidence and the gradual impact of national policy support and capital market reforms.